Hepatic uptake of Tc-99m DPD on bone scintigraphy: the influence of the interval with gadolinium-containing contrast of MRI.
OBJECTIVE
There are various etiologies, which can result in nonosseous, nonurologic uptake in bone scintigraphy. This study aimed to evaluate the influence of the interval between gadolinium (Gd)-containing contrast of MRI and Tc-99m DPD (Tc-99m 3,3-diphosphono-1,2-propanedicarboxylic acid) on bone scintigraphy.


METHODS
We retrospectively analyzed 1028 patients with bone scintigraphy performed between January 2010 and February 2011. All these 1028 patients had MRI contrast administration prior to bone scintigraphy. Fifty patients (8 women, 42 men) showed hepatic uptake on bone scintigraphy. The patients were subdivided into 2 groups (group A: MRI performed on the same day with bone scintigraphy, group B: MRI performed 1 or 2 days before bone scintigraphy).


RESULTS
Among 1028 subjects, hepatic uptake in patients with MRI and bone scintigraphy on the same day was shown in 39 of the 585 bone scintigraphies (6.67%), while hepatic uptake with interval of 1 and 2 days was visualized in 8 of the 186 (4.30%) and 3 of the 87 (3.45%) subjects. No patients with interval more than 2 days showed hepatic uptake of bone scintigraphy.


CONCLUSIONS
The interval between MRI with Gd-contrast and bone scintigraphy has an influence on hepatic uptake. Gd-containing contrast injection before bone scintigraphy within 2 days might affect the nonosseous uptake of Tc-99m DPD. At least 2 days of interval between MRI and bone scintigraphy might be needed to avoid hepatic uptake of bone scintigraphy.
Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.
Kyoungjune
K
Pak
Seong-Jang
SJ
Kim
In Joo
IJ
Kim
Kuen Tak
KT
Suh
D000368:Aged; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D003287:Contrast Media; D004164:Diphosphonates / Q000493:pharmacokinetics*; D005260:Female; D005682:Gadolinium; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging*; D008279:Magnetic Resonance Imaging; D008297:Male; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging; D013154:Spleen / Q000000981:diagnostic imaging; D051598:Whole Body Imaging
D003287:Contrast Media; D004164:Diphosphonates; D015609:Organotechnetium Compounds; C033905:technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid; D005682:Gadolinium